BTCE, Europe’s Leading Physical Bitcoin ETC Announces It’s Going Carbon Neutral
2.7.2021 16:53:00 EEST | Business Wire | Press release
ETC Group has today announced that its leading crypto ETP BTCetc - ETC Group Physical Bitcoin (BTCE) will be the first Bitcoin ETP to go carbon neutral. ETC Group will offset the carbon footprint of BTCE, its flagship Bitcoin ETP, with hand-selected, high quality carbon credits, compensating for the CO2e1 emissions associated with BTCE Bitcoin mining and transaction activities. These carbon credits will support projects curated and managed by some of the most respected climate and conservation groups in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210702005260/en/
ETC Group's Bitcoin Carbon Offset Initiative (Photo: Business Wire)
This latest innovation follows a series of other world firsts. BTCE rose to prominence when it became the first crypto ETP approved by the German regulator BaFin, and the world’s first centrally cleared crypto exchange traded product when it listed on Germany’s Deutsche Börse XETRA exchange in June 20202. BTCE is Europe’s most heavily traded physically backed Bitcoin ETP3.
ETC Group’s co-founder and CEO, Bradley Duke, said “Companies benefiting from cryptocurrencies like bitcoin are right to take meaningful steps to address climate concerns. We are pleased to see that bitcoin miners are increasingly sourcing renewable electricity, but we at ETC Group feel it’s important to do more and act now. That’s why we have launched our initiative to calculate our bitcoin product’s carbon footprint, and offset it with high quality projects curated and monitored by some of the world’s most respected climate action companies.”
ETC Group will fund nature-based, carbon sequestration and renewable energy projects to offset all of its bitcoin-related Scope 3 emissions since the launch of BTCE, and will continue to do so on a quarterly basis. ETC Group also announced that it will join the Crypto Climate Accord, a group that actively seeks to move the entire crypto sector towards low carbon mining and operations, and net zero by 2040.
For more information on the initiative visit www.etc-group.com or contact us at carbonneutral@etc-group.com
Cryptocurrencies are highly volatile and your capital is at risk: https://etc-group.com/resources/disclaimer/etc_group_disclaimer.pdf
- ENDS -
About ETC Group
ETC Group ( www.etc-group.com ) is specialized in developing innovative digital asset-backed securities and is backed by a number of major London-based financial institutions. Shareholders include firms such as XTX Ventures, the venture capital arm of electronic market-making firm XTX Markets. ETC Group’s securities are marketed by HANetf.
1Carbon dioxide equivalent” or “CO2e” is a term for describing different greenhouse gases in a common unit. For any quantity and type of greenhouse gas, CO2e signifies the amount of CO2 which would have the equivalent global warming impact.
2
https://www.xetra.com/xetra-en/newsroom/press-releases/list-press-releases/World-s-first-centrally-cleared-Bitcoin-ETN-launched-on-Xetra-2062116
3
https://www.boerse-frankfurt.de/en/etfs | https://www.hanetf.com/article/740/btcetc-etc-group-physical-bitcoin-btce-is-leading-european-bitcoin-exchange-traded-product-with-45966-million-inflows-in-q1-2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210702005260/en/
Contact information
Paul Cockerton
media@etc-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Expands BlueVerse ™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering23.3.2026 10:30:00 EET | Press release
LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerseTM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale. As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerseTM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems. AppIQ — Modernize Legacy Applications, Faster AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously
Galderma Receives U.S. FDA Approval for Restylane ® Contour™ for the Correction of Temple Hollowing23.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/ With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7 The volume of the temples can dimi
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 06:00:00 EET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 14:58:00 EET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom